Filter Results
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
Clear All
54 Peripheral T-Cell Lymphoma Trials
Power is an online platform that helps thousands of Peripheral T-Cell Lymphoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Patients are in 2 cohorts:
Cohort 1: dexamethasone, methotrexate, ifosfamide, pegaspargase, and etoposide (modified SMILE) chemotherapy regimen alone and pembrolizumab in children, adolescents, and young adults with advanced stage NK lymphoma and leukemia Cohort 2: combining pralatrexate (PRX) (Cycles 1, 2, 4, 6) and brentuximab vedotin (BV) (Cycles 3, 5) to cyclophosphamide, doxorubicin, and prednisone in children, adolescent, and young adults with advanced peripheral T-cell lymphoma (non-anaplastic large cell lymphoma or non-NK lymphoma/leukemia) .
Both groups proceed to allogeneic stem cell transplant with disease response.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:1 - 31
Sex:All
Key Eligibility Criteria
Disqualifiers:Down Syndrome, Active CNS Disease, Others
Must Not Be Taking:CYP3A4 Substrates, Inhibitors, Inducers
40 Participants Needed
This trial studies how well letermovir prevents CMV reactivation in patients with blood cancers treated with alemtuzumab. Letermovir works by stopping the virus from making more copies of itself. The goal is to see if it can effectively prevent CMV infections in these patients. Letermovir is an antiviral drug approved for preventing CMV infections, primarily studied for a few months after treatment.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
6 Participants Needed
Romidepsin Combination Therapy for Lymphoma
Columbus, OhioThe goal of this clinical research study is to learn if giving romidepsin before and after a stem cell transplant in combination with fludarabine and busulfan can help to control leukemia or lymphoma. Researchers also want to learn the highest tolerable dose of romidepsin that can be given with this combination.
The safety of this combination and the safety of giving romidepsin after a stem cell transplant will also be studied.
This is an investigational study. Romidepsin is FDA approved and commercially available for the treatment of CTCL in patients who have received at least 1 systemic (affecting the whole body) therapy before. Busulfan and fludarabine are FDA approved and commercially available for use with a stem cell transplant.
The use of the combination of romidepsin, busulfan, and fludarabine to treat the type of leukemia or lymphoma you have is considered investigational.
Up to 30 participants will be enrolled in this study. All will take part at MD Anderson.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18 - 70
Sex:All
23 Participants Needed
Duvelisib/CC-486 + Chemotherapy for Lymphoma
Columbus, OhioThis phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or worse than the usual approach for treating peripheral T-cell lymphoma.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Pregnancy, CNS Involvement, HTLV, Others
Must Not Be Taking:Strong CYP3A4 Inhibitors, Inducers
170 Participants Needed
DR-01 for Leukemia and Lymphoma
Columbus, OhioThis trial is testing a new drug called DR-01 to see if it is safe and effective for adults with specific blood cancers. The study will check if the drug can safely reach and affect cancer cells to stop their growth.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Active Infection, CNS Malignancy, HIV, Others
Must Not Be Taking:Systemic Corticosteroids, Immunosuppressive Drugs
69 Participants Needed
KT-333 for Lymphoma and Cancer
Columbus, OhioThis trial is testing a new drug called KT-333 in adults with certain cancers that haven't responded to other treatments. The goal is to see if the drug is safe and how it works in the body.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
120 Participants Needed
Brentuximab + Chemotherapy for T-Cell Lymphoma
Columbus, OhioThis phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, etoposide, and prednisone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and combination chemotherapy may work better in treating patients with CD30-positive peripheral T-cell lymphoma.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
48 Participants Needed
DS-3201b for Lymphoma
Columbus, OhioDS-3201b is an experimental drug that is being investigated in clinical research.
Adults with non-Hodgkin lymphoma (NHL) may be able to join this study if their disease has come back after remission or is not responding to current treatment
This study has three parts. The Dose Escalation part is designed is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate. The Dose Expansion phase will determine how effective DS-3201b is for rare types of NH and collect additional safety data. Last, the Drug-Drug Interaction (DDI) Cohort (US Only) will evaluate the effect of DS-3201b on the pharmacokinetics (PK) of midazolam and digoxin when co-administered to patients with NHL
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
100 Participants Needed
Nanatinostat + Valganciclovir for EBV-Positive Lymphoma
Columbus, OhioThis trial tests a combination of nanatinostat and valganciclovir in patients with relapsed or refractory EBV-positive lymphomas. Nanatinostat helps the virus produce proteins that activate valganciclovir to kill cancer cells. The goal is to improve outcomes for these patients. Nanatinostat has shown promise in making EBV-positive lymphoma cells more responsive to antiviral agents.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
140 Participants Needed
CPI-818 for T-Cell Lymphoma
Columbus, OhioThis trial is testing a new pill called CPI-818 for patients with T-cell lymphoma that hasn't responded to other treatments. The pill works by blocking a protein that helps cancer cells grow.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
151 Participants Needed
This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunoblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as anti-ICOS monoclonal antibody MEDI-570, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
21 Participants Needed
Brentuximab Vedotin + CHP for T-Cell Lymphoma
Fairfield, OhioThis clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
82 Participants Needed
AFM13 + AB-101 for Lymphoma
Cleveland, OhioAFM13-203 is a phase 2, open-label, multi-center, multi-cohort study with a safety run-in followed by expansion cohorts. The study is evaluating the safety and efficacy of AFM13 in combination with AB-101 in subjects with R/R classical HL and CD30-positive PTCL.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:CNS Involvement, Hepatitis B/C, HIV, Others
Must Be Taking:Brentuximab Vedotin, PD1 Inhibitors
154 Participants Needed
ONO-4685 for Lymphoma
Cleveland, OhioThis trial will test a new drug called ONO-4685 in patients whose T cell Lymphoma has come back or did not respond to previous treatments. Researchers aim to see if the drug is safe, how it moves through the body, and if it helps reduce the cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:CNS Involvement, ATLL, Others
Must Not Be Taking:Anti-PD-1, Anti-PD-L1
217 Participants Needed
ARV-393 for Non-Hodgkin's Lymphoma
Cleveland, OhioThis clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma to determine if ARV-393 may be a possible treatment option.
ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Transplant, Infection, Lung Disease, Others
112 Participants Needed
Brentuximab Vedotin for T-Cell Lymphoma
Cleveland, OhioThis study will include patients with mature T-cell lymphoma (MTCL) that has been treated with at least one type of chemotherapy, but is not responding or coming back after the previous treatment.
This clinical trial uses a drug called Brentuximab Vedotin. The Food and Drug Administration (FDA) has approved Brentuximab Vedotin for sale in the United States for certain diseases. Brentuximab is still being studied in clinical trials like this one to learn more about what its side effects are and whether or not it is effective in the disease or condition being studied.
Brentuximab Vedotin is a type of drug called an antibody drug conjugate (ADC). ADCs usually have 2 parts; a part that targets cancer cells (the antibody) and a cell killing part (the chemotherapy). Antibodies are proteins that are part of your immune system. They can stick to and attack specific targets on cells. The antibody part of Brentuximab Vedotin sticks to a target called CD30. CD30 is an important molecule on some cancer cells (including non Hodgkin lymphoma) and some normal cells of the immune system. The cell killing part of Brentuximab Vedotin is a chemotherapy called monomethyl auristatin E (MMAE). It can kill cells that the antibody part of Brentuximab Vedotin sticks to. Brentuximab Vedotin has also been shown to kill cancer cells with levels of CD30 that cannot be seen by traditional methods.
This study is being done to test if the study drug has an effect on Mature T cell Lymphoma with such low levels of a target called CD30 and how your disease respond to the study drug.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
23 Participants Needed
Tolinapant + Decitabine/Cedazuridine for Peripheral T-Cell Lymphoma
Ann Arbor, MichiganThe primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:18+
Sex:All
33 Participants Needed
Pembrolizumab + Decitabine + Pralatrexate for T-Cell Lymphoma
Pittsburgh, PennsylvaniaThis is an international, multicenter, multi-arm, phase Ib, model-based dose-escalation study. The primary objectives of the study in each arm is to determine the maximum tolerated dose (MTD), recommended phase 2 dose (RP2D), dose limiting toxicities (DLTs) and to evaluate the clinical efficacy at the MTD of various combinations of pembrolizumab, pralatrexate and decitabine.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 90
Sex:All
Key Eligibility Criteria
Disqualifiers:Active Infection, Autoimmune Disease, Others
Must Not Be Taking:Immunosuppressants, PD-1 Inhibitors
37 Participants Needed
Fenretinide for T-Cell Lymphoma
Ann Arbor, MichiganThis study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:CNS Disease, Hepatitis, HIV, Others
Must Not Be Taking:CYP3A Inducers, CYP3A Inhibitors
46 Participants Needed
IPH4102 for Cutaneous T-Cell Lymphoma
Pittsburgh, PennsylvaniaThis is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
170 Participants Needed
Mogamulizumab for Cutaneous T-Cell Lymphoma
Pittsburgh, PennsylvaniaThis trial is testing a medication called mogamulizumab in adults with certain types of skin cancer that have come back or not responded to other treatments. The medication helps the immune system find and destroy cancer cells. Mogamulizumab is approved for treating various types of skin cancer.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
34 Participants Needed
SIM1811-03 for Cutaneous T-Cell Lymphoma
Detroit, MichiganThis is a first in human, open-label, dose escalation and expansion Phase 1 study of SIM1811-03 in adult patients with advanced solid tumors and cutaneous T-cell lymphoma. SIM1811-03 is a first-in-class IgG1-based humanized anti-tumor necrosis factor type 2 receptor (TNFR2) monoclonal antibody for the treatment of malignant tumors.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, CNS Metastases, Others
Must Not Be Taking:Corticosteroids, Cytotoxic Chemotherapy
100 Participants Needed
Pembrolizumab + Mogamulizumab for Cutaneous T-Cell Lymphoma
Ann Arbor, MichiganThis is an open-label, single-arm, multicenter, phase II study combining pembrolizumab and mogamulizumab in patients with advanced-stage, relapsed or refractory CTCL Each cycle will equal 6 weeks. Pembrolizumab will be administered on Day 1 of each cycle. Mogamulizumab will be administered on Day 1, 8, 15, and 22 of Cycle 1. For Cycle 2 and subsequent cycles, mogamulizumab will be administered on Day 1, 15 and 29 of each cycle. Subjects will undergo a response assessment prior to Cycle 3 and every 2 cycles thereafter.
Subjects will continue study treatment until documented progression, unacceptable toxicity, or any other condition for discontinuation is met in protocol. A maximum of 2 years of study treatment may be administered. If a subject achieves a complete response (CR) per mSWAT criteria after 3 months of study treatment (2 cycles), they will continue study therapy for an additional 6 months (4 cycles). If a confirmed and persistent CR is met, they may discontinue study treatment and enter an observation period in protocol. Repeat disease evaluation is required prior to study therapy discontinuation. Subjects who progress during the observation period may be eligible for up to an additional 9 cycles (1 year) of pembrolizumab and mogamulizumab.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis B/C, Autoimmune, Others
Must Not Be Taking:Immunosuppressants, Checkpoint Inhibitors
23 Participants Needed
HyBryte Cream for Cutaneous T-Cell Lymphoma
Pittsburgh, PennsylvaniaTo evaluate the use of HyBryte, a topical photosensitizing agent, to treat patients with patch/plaque phase cutaneous T-cell lymphoma (mycosis fungoides).
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Sun Hypersensitivity, Allergy To HyBryte, Others
Must Not Be Taking:Topical Steroids, Systemic Steroids
80 Participants Needed
Belinostat/Pralatrexate + CHOP for T-Cell Lymphoma
Louisville, KentuckyThis trial is testing two new drugs, Belinostat and Pralatrexate, combined with standard chemotherapy in patients with newly diagnosed PTCL. The goal is to find the safest and most effective dose. The new drugs work by either blocking cancer cell growth or tricking cancer cells into absorbing a harmful substance. Pralatrexate is a specially designed drug with greater preclinical antitumor activity than methotrexate.
No Placebo Group
Pivotal Trial
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:Precursor T-cell Lymphoma, Others
Must Not Be Taking:UGT1A1 Inhibitors, HDAC Inhibitors
504 Participants Needed
PRT2527 + Zanubrutinib for Blood Cancers
Charlottesville, VirginiaThis trial is testing a new drug called PRT2527, which blocks a protein that helps cancer cells grow, in patients with certain blood cancers that have come back or did not respond to other treatments. It also tests PRT2527 in combination with another drug, zanubrutinib, which blocks a different protein involved in cancer growth. The goal is to find a safe and effective dose for these drugs.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
86 Participants Needed
Azacytidine + Romidepsin for Peripheral T-Cell Lymphoma
Charlottesville, VirginiaThis trial is testing if a combination of two drugs, romidepsin and azacytidine, is safe and effective for patients with aggressive Peripheral T-Cell Lymphoma that hasn't responded to other treatments. The goal is to see if this combination works better than using just one drug alone. Romidepsin is approved for certain types of T-cell lymphoma and has shown positive results in various T-cell cancers.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
Key Eligibility Criteria
Disqualifiers:HIV, Hepatitis, CNS Metastases, Others
Must Not Be Taking:CYP3A4 Inhibitors, QT Prolongation Drugs
50 Participants Needed
Valemetostat for T-Cell Lymphoma
Chicago, IllinoisThis study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18+
Sex:All
155 Participants Needed
SGN-35T for Lymphoma
Chicago, IllinoisThis trial is testing a new drug in adults with certain types of lymphoma that haven't responded to other treatments. The drug works by targeting a protein on cancer cells and delivering a substance that kills them. This drug has shown high selectivity against specific cancer cells and has been approved for treating lymphoma patients.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Age:18+
Sex:All
110 Participants Needed
APR-TD011 Spray for Cutaneous T-Cell Lymphoma
Chicago, IllinoisThis trial is testing a special spray that cleans wounds on patients with a type of skin cancer called CTCL. The goal is to see if the spray is well-tolerated and if it changes the bacteria on the skin. The spray could help improve the condition of the skin lesions.
No Placebo Group
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Early Phase 1
Age:18+
Sex:All
30 Participants Needed
Page 1 of 2+
Frequently Asked Questions
How much do Peripheral T-Cell Lymphoma clinical trials pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Peripheral T-Cell Lymphoma clinical trials work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Peripheral T-Cell Lymphoma trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Peripheral T-Cell Lymphoma is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Peripheral T-Cell Lymphoma medical study ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Peripheral T-Cell Lymphoma clinical trials ?
Most recently, we added HyBryte Cream for Cutaneous T-Cell Lymphoma, APR-TD011 Spray for Cutaneous T-Cell Lymphoma and Enasidenib for T-Cell Lymphoma to the Power online platform.